Neogen Corporation (NEOG) Institutional Ownership & Insider Trading

316 institutions reported holding Neogen Corporation shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 7 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-08-31 · read by EquiReason

NEOGNeogen CorporationFollow NEOG — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 2.7B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 6 Jan, in 74 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

316 institutions held —% of the shares. Across filers that reported both quarters, shares held changed +1.9%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	316	237	+1.9%	86	37	98	31
Mar 26	307	233	+5.2%	98	35	86	29
Dec 25	303	224	-8.0%	81	34	95	35
Sep 25	294	240	+1.1%	90	29	110	55
Jun 25	315	240	-11.1%	104	59	94	76
Mar 25	334	258	+0.1%	108	41	110	45
Dec 24	341	267	+4.7%	103	25	117	28
Sep 24	331	235	-1.7%	110	18	98	24

Neogen Corporation — questions

Who owns Neogen Corporation stock?: 316 institutions reported Neogen Corporation shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (15.3%), NEUBERGER BERMAN GROUP LLC (7.6%), VANGUARD PORTFOLIO MANAGEMENT LLC (6.0%).
Are Neogen Corporation insiders buying or selling?: 7 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Neogen Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.